Iron supplementation and erythropoiesis-stimulatory agents in the treatment of cancer anemia

Paolo Pedrazzoli, Giovanni Rosti, Simona Secondino, Salvatore Siena

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Unresponsiveness to erythropoiesis-stimulatory agents (ESA), which occurs in 30% to 50% of patients, is a major limitation to the treatment of chemotherapy-related anemia (CRA). This may be related in part to the dysregulation of iron metabolism, leading to functional iron deficiency. However, the use of iron supplementation during treatment with ESA has not been pursued as rigorously in anemic patients with cancer as it has in patients with chronic kidney disease. In this article, the authors discuss the role of iron supplementation in the setting of CRA in view of recent reports that have addressed this issue.

Original languageEnglish
Pages (from-to)1169-1173
Number of pages5
JournalCancer
Volume115
Issue number6
DOIs
Publication statusPublished - Mar 15 2009

Fingerprint

Erythropoiesis
Anemia
Iron
Neoplasms
Drug Therapy
Therapeutics
Chronic Renal Insufficiency

Keywords

  • Cancer anemia
  • Chemotherapy
  • Erythropoiesis-stimulatory agents
  • Iron supplementation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Iron supplementation and erythropoiesis-stimulatory agents in the treatment of cancer anemia. / Pedrazzoli, Paolo; Rosti, Giovanni; Secondino, Simona; Siena, Salvatore.

In: Cancer, Vol. 115, No. 6, 15.03.2009, p. 1169-1173.

Research output: Contribution to journalArticle

@article{512aa768757d4b728dc207c85f5bd3f5,
title = "Iron supplementation and erythropoiesis-stimulatory agents in the treatment of cancer anemia",
abstract = "Unresponsiveness to erythropoiesis-stimulatory agents (ESA), which occurs in 30{\%} to 50{\%} of patients, is a major limitation to the treatment of chemotherapy-related anemia (CRA). This may be related in part to the dysregulation of iron metabolism, leading to functional iron deficiency. However, the use of iron supplementation during treatment with ESA has not been pursued as rigorously in anemic patients with cancer as it has in patients with chronic kidney disease. In this article, the authors discuss the role of iron supplementation in the setting of CRA in view of recent reports that have addressed this issue.",
keywords = "Cancer anemia, Chemotherapy, Erythropoiesis-stimulatory agents, Iron supplementation",
author = "Paolo Pedrazzoli and Giovanni Rosti and Simona Secondino and Salvatore Siena",
year = "2009",
month = "3",
day = "15",
doi = "10.1002/cncr.24115",
language = "English",
volume = "115",
pages = "1169--1173",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Iron supplementation and erythropoiesis-stimulatory agents in the treatment of cancer anemia

AU - Pedrazzoli, Paolo

AU - Rosti, Giovanni

AU - Secondino, Simona

AU - Siena, Salvatore

PY - 2009/3/15

Y1 - 2009/3/15

N2 - Unresponsiveness to erythropoiesis-stimulatory agents (ESA), which occurs in 30% to 50% of patients, is a major limitation to the treatment of chemotherapy-related anemia (CRA). This may be related in part to the dysregulation of iron metabolism, leading to functional iron deficiency. However, the use of iron supplementation during treatment with ESA has not been pursued as rigorously in anemic patients with cancer as it has in patients with chronic kidney disease. In this article, the authors discuss the role of iron supplementation in the setting of CRA in view of recent reports that have addressed this issue.

AB - Unresponsiveness to erythropoiesis-stimulatory agents (ESA), which occurs in 30% to 50% of patients, is a major limitation to the treatment of chemotherapy-related anemia (CRA). This may be related in part to the dysregulation of iron metabolism, leading to functional iron deficiency. However, the use of iron supplementation during treatment with ESA has not been pursued as rigorously in anemic patients with cancer as it has in patients with chronic kidney disease. In this article, the authors discuss the role of iron supplementation in the setting of CRA in view of recent reports that have addressed this issue.

KW - Cancer anemia

KW - Chemotherapy

KW - Erythropoiesis-stimulatory agents

KW - Iron supplementation

UR - http://www.scopus.com/inward/record.url?scp=63449089728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63449089728&partnerID=8YFLogxK

U2 - 10.1002/cncr.24115

DO - 10.1002/cncr.24115

M3 - Article

VL - 115

SP - 1169

EP - 1173

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -